AIP insider filings show recent 10b5-1 and ad hoc sales
Rhea-AI Filing Summary
Arteris, Inc. reported a Form 144 notice for the proposed sale of 5,755 common shares with an aggregate market value of $63,189.90, showing an approximate sale date of 10/06/2025 on NASDAQ. The securities were originally acquired on 06/16/2014 in a private acquisition from the issuer and paid for in cash. The filing lists multiple recent dispositions by the related party, including several 10b5-1 sales and direct sales by K. CHARLES JANAC totalling sizeable proceeds in August–October 2025 (examples: $1,271,120.01 for 94,245 shares on 08/05/2025; $655,995.00 for 50,000 shares on 08/05/2025). The filing includes the required representation that the seller is not aware of undisclosed material adverse information.
Positive
- Planned 10b5-1 trades are listed for several transactions, indicating use of pre-arranged trading plans
- Broker involvement noted (Morgan Stanley Smith Barney LLC), suggesting professional execution and recordkeeping
Negative
- Recent large insider sales include 94,245 shares for $1,271,120.01 and 50,000 shares for $655,995.00 on 08/05/2025, increasing available insider supply
- Form 144 lacks a stated 10b5-1 plan adoption date within the remarks, leaving timing of pre‑arranged instructions unclear in this filing
Insights
Small scheduled Rule 144 sale follows several recent 10b5-1 and ad hoc dispositions.
The notice covers 5,755 shares valued at $63,189.90 with an approximate sale date of 10/06/2025, while the schedule of recent sales shows multiple larger transactions, including 94,245 shares for $1,271,120.01 and 50,000 shares for $655,995.00 on 08/05/2025. These entries include both labeled 10b5-1 plan sales and direct sales by K. CHARLES JANAC, indicating a mix of pre-arranged and discretionary dispositions.
The pattern suggests staged liquidity events rather than a single large block sale; monitor whether further 10b5-1 notices or additional Form 144 filings appear in the next 30–90 days to assess ongoing insider supply pressure.
The filing documents compliance with Rule 144 mechanics and includes a standard representation about material non‑public information.
The securities to be sold were acquired from the issuer on 06/16/2014 and paid in cash, and the notice names the executing broker as Morgan Stanley Smith Barney LLC. Several prior sales in the past three months are itemized with dates and gross proceeds, and some are explicitly identified as 10b5-1 plan trades, which provides an affirmative defense if properly adopted and executed.
Absent a disclosed plan adoption date in this form, stakeholders may look for accompanying 10b5-1 plan documentation or check periodic filings for the plan adoption date to confirm the timing and compliance of pre-arranged trades within the next regulatory reporting cycle.